Cullgen Founders Disclose 8.6% Stake in Gyre Therapeutics Post-Merger, Detailing Preferred Stock & Lock-Up Terms
GYRE sits 22% above its 52-week low of $6.57.
Summary
Ying Luo and Ping Lan, key figures from acquired Cullgen Inc., have disclosed a combined 8.6% beneficial ownership in Gyre Therapeutics following the $300 million all-stock merger, with their shares subject to lock-up agreements and specific Series B Preferred Stock conversion terms.
Key Events · Ownership and Investor Activity · GYRE
-
Significant Beneficial Ownership
Ying Luo and Ping Lan (spouse), key figures from the acquired Cullgen Inc., now beneficially own 8.6% of Gyre Therapeutics' common stock, totaling 10,211,387 shares, following the merger.
-
Post-Merger Capital Structure Details
The filing details the issuance of Series B Preferred Stock as part of the $300 million all-stock acquisition of Cullgen, which is convertible into common stock and includes specific voting rights and protective provisions for holders.
-
Conversion Cap & Shareholder Vote
Conversion of Series B Preferred Stock is initially capped at 19.99% of outstanding common stock, pending shareholder approval at a meeting scheduled for June 10, 2026.
-
Lock-Up Agreements Imposed
Shares held by certain executives, directors, and stockholders from both Gyre and Cullgen are subject to staggered lock-up periods of 180 days, 12 months, and 18 months, restricting immediate sales.
Analysis · GYRE · Life Sciences
This Schedule 13D/A filing provides crucial details regarding the post-merger capital structure and significant ownership by the former leadership of Cullgen Inc., which Gyre Therapeutics recently acquired. Ying Luo and his spouse, Ping Lan, now beneficially own 8.6% of Gyre Therapeutics, a substantial stake that aligns their interests with the combined entity's success. The filing outlines the terms of the Series B Preferred Stock issued in the merger, which includes voting rights and a temporary conversion cap of 19.99% until shareholder approval, indicating potential future dilution. Additionally, the disclosure of lock-up agreements for these shares provides clarity on the near-term selling pressure from these key holders, suggesting a commitment to the long-term value creation of the combined company.
At the time of this filing, GYRE was trading at $8.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $779.8M. The 52-week trading range was $6.57 to $11.78. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.